The evidence above may suggest further exploration of the insulin signaling pathway regulated by PPARγ SUMOylation, and inhibition of PPARγ SUMOylation is a potential way to design novel anti-T2D vascular complications drugs. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.